191 related articles for article (PubMed ID: 38170551)
1. New strategies for the management of triple-negative breast cancer.
Riaz F
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):40-44. PubMed ID: 38170551
[TBL] [Abstract][Full Text] [Related]
2. Triple negative breast cancer: any closer to cracking the code?
Peddi PF
Curr Opin Obstet Gynecol; 2022 Feb; 34(1):52-55. PubMed ID: 34967815
[TBL] [Abstract][Full Text] [Related]
3. Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.
Torres ETR; Emens LA
Breast Cancer Res Treat; 2022 Jan; 191(2):291-302. PubMed ID: 34716871
[TBL] [Abstract][Full Text] [Related]
4. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
5. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.
Mohamed A; Kruse M; Tran J
Expert Rev Anticancer Ther; 2023; 23(10):1071-1084. PubMed ID: 37747062
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
Song F; Tarantino P; Garrido-Castro A; Lynce F; Tolaney SM; Schlam I
Curr Oncol Rep; 2024 Jan; 26(1):21-33. PubMed ID: 38198112
[TBL] [Abstract][Full Text] [Related]
7. The Evolving Landscape of Immune Checkpoint Inhibitors and Antibody Drug Conjugates in the Treatment of Early-Stage Breast Cancer.
Bhardwaj PV; Abdou YG
Oncologist; 2023 Oct; 28(10):832-844. PubMed ID: 37597245
[TBL] [Abstract][Full Text] [Related]
8. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
9. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
Rizzo A; Cusmai A; Acquafredda S; Giovannelli F; Rinaldi L; Misino A; Palmiotti G
Future Oncol; 2022 Jun; 18(18):2301-2309. PubMed ID: 35378995
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in antibody-based therapeutics for triple-negative breast cancer.
Ning WJ; Liu X; Zeng HY; An ZQ; Luo WX; Xia NS
Expert Opin Drug Deliv; 2022 Jul; 19(7):815-832. PubMed ID: 35738312
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
12. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
[TBL] [Abstract][Full Text] [Related]
13. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
[TBL] [Abstract][Full Text] [Related]
14. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in targeted strategies for triple-negative breast cancer.
Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
[TBL] [Abstract][Full Text] [Related]
17. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Steiner M; Tan AR
Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
[TBL] [Abstract][Full Text] [Related]
18. Targeted Treatment of Triple-Negative Breast Cancer.
Young JA; Tan AR
Cancer J; 2021 Jan-Feb 01; 27(1):50-58. PubMed ID: 33475293
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer?
Palleschi M; Maltoni R; Sarti S; Melegari E; Bravaccini S; Rocca A
Breast J; 2020 Apr; 26(4):739-742. PubMed ID: 31612573
[TBL] [Abstract][Full Text] [Related]
20. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking.
He R; Yuan X; Chen Z; Zheng Y
Int Immunopharmacol; 2022 Dec; 113(Pt B):109444. PubMed ID: 36402069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
